Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
---|---|---|---|---|---|---|---|---|
2024-09-18 | BIOLIFE SOLUTIONS INC | Mathew Aby J.
(EVP & Chief Scientific Officer) |
S | Common Stock | D | 20000 | $23.90 - $25.47 | $493,700 |
2024-09-17 | Neumora Therapeutics, Inc. | Lenz Robert A.
(Head of R&D) |
S | Common Stock | D | 41464 | $11.81 - $12.09 | $492,825 |
A | Grant, award or other acquisition |
C | Conversion of Derivative or Security |
D | Disposition to the issuer of issuer equity securities |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability |
G | Bona fide Gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary Transaction |
J | Other acquisition or disposition |
K | Transaction in equity swap or instrument with similar characteristics |
L | Small Acquisition |
M | Exercise or conversion of derivative security |
O | Exercise of out-of-the-money derivative security |
P | Open Market Purchase |
S | Open Market Sale |
U | Disposition pursuant to a tender of shares in a change of control transaction |
V | Transaction Voluntarily Reported |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |